EQT Announces Proposed €9.6 Billion Acquisition Offer for QIAGEN

On 21 October, EQT’s acquisition vehicle announced a voluntary all-cash offer of €46.50 per QIAGEN share, valuing the Dutch-headquartered life-sciences company’s equity at approximately €9.6 billion. The offer is a proposed takeover rather than a completed transaction, and completion depends on the applicable offer process and conditions. Investors and corporate-finance advisers can explore transaction valuation, financial modelling and due diligence; HPC can support complex financial analysis and data-intensive workloads through a tailored quotation.

If you are interested to enquire further, please fill in the form below with your details and one of our consultants will contact you shortly.